



# Counterparty Credit Risk

Presenter: Joleen Wingyou



# Regulation

- **Additions:**
  - **Stressed Effective Expected Positive Exposure**
  - **Standardised Credit Valuation Adjustment**
  - **Advanced Credit Valuation Adjustment**
  - **Analysis of standardised CVA risk weighted exposure**



# Form BA 200

(All amounts to be rounded off to the nearest R'000)

| Standardised approach:<br>Counterparty credit risk <sup>1</sup> | Line no. | Current exposure method             |                        |                      |  |                                      |                                |  |                  |                  | Standardised method               |                                    |                               |                               |  |
|---|----------|-------------------------------------|------------------------|----------------------|--|--------------------------------------|--------------------------------|--|------------------|------------------|-----------------------------------|------------------------------------|-------------------------------|-------------------------------|--|
|   |          | OTC derivative instruments          |                        |                      |  |                                      |                                | SFT <sup>2</sup>   |                  |                  | OTC derivative instruments        |                                    |                               |                               |  |
|   |          | Total notional principal amount     | Gross replacement cost | Net replacement cost | Gross potential future exposure add-on | Net potential future exposure add-on | Collateral value after haircut | Credit exposure value  | Collateral value | Netting benefits | Current market value of portfolio | Current market value of collateral | Risk position for transaction | Risk position from collateral | Net absolute risk position after the application of CCFs |
|   |          | 1                                   | 2                      | 3                    | 4                                      | 5                                    | 6                              | 7  | 8                | 9                | 10                                | 11                                 | 12                            | 13                            | 14   |
| Total (of items 81 to 85)                                       | 80       |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |
| 0%  | 81       | $EAD = [(RC + \text{Add-on})] - Ca$ |                        |                      |  |                                      |                                | $EAD = \beta \cdot \max(CMV - CMC; \sum  \sum RPT - \sum RPC  \times CCF)$ |                  |                  |                                   |                                    |                               |                               |  |
| 20%   | 82       |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |
| 50%   | 83       |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |
| 100%  | 84       |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |
| 150%  | 85       |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |
| Memorandum items:   |          |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |
| Maximum counterparty credit exposure during the month           | 86       |                                     |                        |                      |  |                                      |                                |  |                  |                  |                                   |                                    |                               |                               |  |

$$EAD = [(RC + \text{Add-on})] - Ca$$

Comprehensive approach for collateral in Reg 23(8) & 23 (9)

$$EAD = \beta \cdot \max(CMV - CMC; \sum |\sum RPT - \sum RPC| \times CCF)$$

Reporting columns based on the counterparty credit risk methods as specified in Regulation 23 (17) – 23 (19)

# Form BA 200 (continued)

(All amounts to be rounded off to the nearest R'000)

| Standardised approach;<br>Counterparty credit risk <sup>1</sup> | Line<br>no. | Standardised method         |                     |                    | Internal model <sup>3</sup>                   |   |   |   | Aggregate total across all relevant approaches |  |                                  |                  |                         |          |       |
|---|-------------|-----------------------------|---------------------|--------------------|---|---|---|---|--|--|----------------------------------|------------------|-------------------------|----------|-------|
|   |             | SFT <sup>2</sup>            |                     |                    | OTC derivative<br>instruments                 |   | SFT <sup>2</sup>                              |   | Adjusted exposure<br>amount                    |  | Risk weighted exposure           |                  |                         |          |       |
| Analysis of OTC derivative<br>instruments and SFT <sup>2</sup>  |             | Credit<br>exposure<br>value | Collateral<br>value | Netting<br>benefit | Effective<br>expected<br>positive<br>exposure | Stressed<br>effective<br>expected<br>positive<br>exposure | Effective<br>expected<br>positive<br>exposure | Stressed<br>effective<br>expected<br>positive<br>exposure | OTC<br>derivative<br>instruments               | EAD/<br>Credit<br>Exposure<br>SFT <sup>2</sup> * | Default risk                     |                  | CVA <sup>4,5</sup> risk |          | Total |
|   |             |                             |                     |                    |   |   |   |   |  |  | OTC<br>derivative<br>instruments | SFT <sup>2</sup> | Standar<br>dised        | Advanced |       |
| Based on specified risk<br>weights                              |             | 15                          | 16                  | 17                 | 18  | 19  | 20  | 21  | 22   | 23   | 24                               | 25               | 26                      | 27       | 28    |
| <b>Total</b> (of items 81 to 85)                                | 80          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| 0%  | 81          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| 20%   | 82          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| 50%   | 83          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| 100%  | 84          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| 150%  | 85          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| <b>Memorandum items:</b>  |             |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |
| Maximum counterparty credit<br>exposure during the month        | 86          |                             |                     |                    |   |   |   |   |  |  |                                  |                  |                         |          |       |

Comprehensive approach for collateral in Reg 23(8) & 23 (9)

\*EAD calculated under Basel II counterparty credit risk methods



# Form BA 200 (continued)

(All amounts to be rounded off to the nearest R'000)

| Analysis of standardised CVA <sup>1</sup> risk weighted exposure | Line no | Weight | EAD <sup>*</sup> | Hedging         |           | Standardised CVA <sup>1</sup> risk weighted exposure <sup>2</sup> |
|--|---------|--------|------------------|-----------------|-----------|---|
|  |         |        |                  | Single name CDS | Index CDS |   |
| Ratings  |         | 1      | 2                | 3               | 4         | 5   |
| AAA  | 92      | 0.70%  |                  |                 |           |   |
| AA   | 93      | 0.70%  |                  |                 |           |   |
| A  | 94      | 0.80%  |                  |                 |           |   |
| BBB  | 95      | 1.00%  |                  |                 |           |   |
| BB   | 96      | 2.00%  |                  |                 |           |   |
| B  | 97      | 3.00%  |                  |                 |           |   |
| CCC  | 98      | 10.00% |                  |                 |           |   |
| <b>Total (of items 92 to 98)</b>                                 | 99      |        |                  |                 |           |   |

**Draft 3: Regulation 23 (15)(f)**

**Unrated counterparties: Basel II principles – BBB**

**Starting point: EAD calculated under normal Basel II counterparty credit risk methods (CEM, SM or IMM)**

**\* Adjusted for a discounting factor  $(1 - \exp(-0.05 * \text{Mind})) / (0.05 * \text{Mind})$**



# BA 610

| E.4 CREDIT RISK   |          | (All amounts to be rounded off to the nearest '000) |                  |                            |                  |                       |          |
|---|----------|---|------------------|----------------------------|------------------|-----------------------|----------|
|   |          | Aggregate total across all relevant                 |                  |                            |                  |                       |          |
| Standardised / IRB approach:<br>Counterparty credit risk <sup>1</sup><br>Analysis of OTC derivative instruments and SFT <sup>2</sup><br>Based on specified risk weights | Line no. | Adjusted exposure amount <sup>1</sup>               |                  | Risk weight                |                  |                       |          |
|   |          | OTC derivative instruments                          | SFT <sup>2</sup> | Default risk <sup>3</sup>  |                  | CVA <sup>4</sup> risk |          |
|   |          |   |                  | OTC derivative instruments | SFT <sup>2</sup> | Standardised          | Advanced |
|   |          | 1   | 2                | 3                          | 4                | 5                     | 6        |
| Total   | 237      |   |                  |                            |                  |                       |          |

Intra group bank exposures are exempted from the CVA calculation



# Key points:

- **Counterparty credit risk section: IRB & SA.**
- **CVA charge: When the majority of the bank's credit exposure is subject to the IRB approach the bank shall complete the relevant required information specified in items 252 to 281 of the form BA 200, and leave open the relevant columns under the standardised approach.**
- **Ensure the "Basel II" CCR information is reported correctly.**



# Reporting on risk weighted exposures

## Bilateral trades

| Standardised approach/<br>IRB Approach:<br>Counterparty credit risk <sup>1</sup> | Line no.                                     | Aggregate total across all relevant approaches              |                  |                            |                  |                                 |                             |                              |
|--|--|---|------------------|----------------------------|------------------|---------------------------------|-----------------------------|------------------------------|
|  |  | Adjusted exposure amount                                    |                  | Risk weighted exposure     |                  |                                 |                             |                              |
|  |  | OTC derivative instruments                                  | SFT <sup>2</sup> | Default risk               |                  | Standardised CVA <sup>4,5</sup> | Advanced CVA <sup>4,5</sup> | Total risk weighted exposure |
|  |  |   |                  | OTC derivative instruments | SFT <sup>2</sup> |                                 |                             |                              |
| Analysis of OTC derivative instruments and SFT <sup>2</sup>                      |  |   |                  |                            | 26               | 27                              | 28                          |                              |
| STA: RW %<br>IRB: PD bands   | STA: lines 80 to 85<br>IRB; lines 252 to 280 | Should include all trades where CVA should be calculated on |                  |                            |                  |                                 |                             |                              |

Include CVA on bilateral trades

| Analysis of central counterparty trade exposure                           | Line no | Trade exposure | Risk weight | RWA |
|---|---------|----------------|-------------|-----|
| Exposures eligible for a 2% risk weight                                   |         | 1              | 2           | 3   |
| Exposures eligible for a 4% risk weight                                   |         |                | 4%          |     |
| Exposures eligible for a bilateral risk weight                            |         |                |             |     |
| <b>Total central counterparty exposures (total of items (295 to 297))</b> |         |                |             |     |

| Analysis of standardised CVA <sup>1</sup> risk weighted exposure | Line no | Weight | EAD | Hedging         |           | Standardised CVA <sup>1</sup> risk weighted exposure <sup>2</sup> |
|--|---------|--------|-----|-----------------|-----------|---|
|  |         |        |     | Single name CDS | Index CDS |   |
|  |         |        |     | 1               | 2         |   |
| AAA  |         | 0.70%  |     |                 |           |   |
| AA   |         | 0.70%  |     |                 |           |   |
| A  |         | 0.80%  |     |                 |           |   |
| BBB  |         | 1.00%  |     |                 |           |   |
| BB   |         | 2.00%  |     |                 |           |   |
| B  |         | 3.00%  |     |                 |           |   |
| CCC  |         | 10.00% |     |                 |           |   |
| <b>Total (of items 287 to 293)</b>                               |         |        |     |                 |           |   |

Include CVA on bilateral trades

# Reporting on risk weighted exposures

## Trade exposure to a non-qualifying CCP

Banks must apply the **Standardised Approach for credit risk** in the main framework, according to the category of the counterparty, to their trade exposure to a non-qualifying CCP.

| Analysis of central counterparty trade exposure                           | Line no | Trade exposure | Risk weight | RWA |
|---|---------|----------------|-------------|-----|
|   |         | 1              | 2           | 3   |
| Exposures eligible for a 2% risk weight                                   |         |                | 2%          |     |
| Exposures eligible for a 4% risk weight                                   |         |                | 4%          |     |
| Exposures eligible for a bilateral risk weight                            |         |                |             |     |
| <b>Total central counterparty exposures (total of items (295 to 297))</b> |         |                |             |     |

Should include trade exposure to non-QCCP

Should include RWE to non-QCCP



# Reporting on risk weighted exposures

## Total CCR risk weighted Exposure

| Standardised approach/<br>IRB Approach:<br>Counterparty credit risk <sup>1</sup> | Line no.                                     | Aggregate total across all relevant approaches |                  |                            |                  |                                 |                             | Total risk weighted exposure |  |
|--|--|--|------------------|----------------------------|------------------|---------------------------------|-----------------------------|------------------------------|--|
|  |  | Adjusted exposure amount                       |                  | Risk weighted exposure     |                  |                                 |                             |                              |  |
|  |  |  |                  | Default risk               |                  | Standardised CVA <sup>4,5</sup> | Advanced CVA <sup>4,5</sup> |                              |  |
|  |  | OTC derivative instruments                     | SFT <sup>2</sup> | OTC derivative instruments | SFT <sup>2</sup> |                                 |                             |                              |  |
| Analysis of OTC derivative instruments and SFT <sup>2</sup>                      |  | 22   | 23               | 24                         | 25               | 26                              | 27                          | 28                           |  |
| STA: RW %<br>IRB: PD bands   | STA: lines 80 to 85<br>IRB; lines 252 to 280 |  |                  |                            |                  |                                 |                             |                              |  |

| Analysis of central counterparty trade exposure                           | Line no | Trade exposure | Risk weight | RWA |
|---|---------|----------------|-------------|-----|
| Exposures eligible for a 2% risk weight                                   |         | 1              | 2           | 3   |
| Exposures eligible for a 4% risk weight                                   |         |                | 2%          |     |
| Exposures eligible for a bilateral risk weight                            |         |                |             |     |
| <b>Total central counterparty exposures (total of items (295 to 297))</b> |         |                |             |     |

Excluding bilateral trades included in col 1 to 25

| Qualifying central counterparty default fund guarantees | Line no | Initial margin collateral posted with the CCP | Prefunded default fund contribution | Trade exposure | RWA |
|---|---------|---|-------------------------------------|----------------|-----|
|   |         | 1   | 2                                   | 3              | 4   |
| Total   | 299     |   |                                     |                |     |

| Non-qualifying central counterparty default fund guarantees | Line no | Prefunded default fund contribution | Unfunded default fund contribution | RWA |
|---|---------|-------------------------------------|------------------------------------|-----|
|   |         | 1                                   | 2                                  | 3   |
| Total   | 301     |                                     |                                    |     |

# Reporting on risk weighted exposures

## Total CREDIT risk weighted Exposure

| Standardised approach/<br>IRB Approach:<br>Counterparty credit risk <sup>1</sup><br><br>Analysis of OTC derivative<br>instruments and SFT <sup>2</sup> | Line no.                                     | Aggregate total across all relevant approaches |                  |                                  |                  |                                    |                                |    |                                    |
|--|--|--|------------------|----------------------------------|------------------|------------------------------------|--------------------------------|----|------------------------------------|
|  |  | Adjusted exposure<br>amount                    |                  | Risk weighted exposure           |                  |                                    |                                |    | Total risk<br>weighted<br>exposure |
|  |  |  |                  | Default risk                     |                  | Standardised<br>CVA <sup>4,5</sup> | Advanced<br>CVA <sup>4,5</sup> |    |                                    |
|  |  | OTC<br>derivative<br>instruments               | SFT <sup>2</sup> | OTC<br>derivative<br>instruments | SFT <sup>2</sup> |                                    |                                |    |                                    |
|  |  | 22   | 23               | 24                               | 25               | 26                                 | 27                             | 28 |                                    |
| STA: RW %<br>IRB: PD bands   | STA: lines 80 to 85<br>IRB: lines 252 to 280 |  |                  |                                  |                  |                                    |                                |    |                                    |

| Standardised approach/IRB Approach<br>Summary of on-balance sheet and off-balance sheet credit exposure | Line no. |
|---|----------|
| Asset class   |          |
| Corporate exposure (total of items)   |          |
| ...   |          |
| ...   |          |
| Public sector entities  |          |
| Local government and municipalities   |          |
| Sovereign (including central government and central bank)   |          |
| Banks   |          |
| Securities firms  |          |
| Retail exposure (total of items)  |          |
| ...   |          |
| ...   |          |
| Securitisation and resecuritisation exposure <sup>7</sup>   |          |
| <b>Total (of items)</b>   |          |

STA: Lines 14 to 34  
IRB: lines 129 to 156

### Total risk weighted exposure

Includes  
default risk  
RWE for CCR

Sum of  
- RWE per assets classes  
- RWE held for CVA and CCPs

STA:  
lines 14 to 33 col 16  
**plus**  
Line 80 col 28  
**less**  
line 80 col 24 and 25

IRB:  
lines 129 to 155 col 10  
**plus**  
Line 280 col 28  
**less**  
line 280 col 24 and 25

